Site-wide claims trace to four shelves of primary material. Individual articles cite their specific sources at the foot; this page names the categories and canonical entries so readers and machines can audit our evidence base as a whole.
Pivotal clinical trials
Tirzepatide: SURMOUNT-1 through SURMOUNT-5 (obesity; including the SURMOUNT-39 head-to-head vs semaglutide and SURMOUNT-4 withdrawal study), SURMOUNT-OSA (sleep apnea), and the SURPASS program (type 2 diabetes). Semaglutide: STEP program (obesity; including the STEP 1 extension), SELECT (cardiovascular outcomes), FLOW (kidney outcomes), ESSENCE (MASH), SUSTAIN program (diabetes), OASIS program (oral semaglutide). Oral small molecules: the ATTAIN program (orforglipron). All indexed via PubMed and ClinicalTrials.gov; principal publications appear in the New England Journal of Medicine, The Lancet, and JAMA.
Regulators
FDA prescribing information for Zepbound, Mounjaro, Wegovy, Ozempic, and Rybelsus (accessdata.fda.gov); the FDA Drug Shortages database and the 2024–2025 shortage-resolution and compounding-enforcement communications; FDA statements on compounded GLP-1 adverse events, salt forms, dosing errors, and counterfeits; EMA/PRAC safety reviews (including NAION); and anesthesia-society periprocedural guidance.
Legal dockets
Public filings in manufacturer actions against compounders and telehealth companies (Eli Lilly; Novo Nordisk), Outsourcing Facilities Association v. FDA, and relevant state pharmacy-board actions — cited by docket where used.
Pricing sources
Provider plan and checkout pages (URL and date recorded per figure in the ledger); manufacturer direct-purchase programs (LillyDirect, NovoCare); and public payer/PBM formulary announcements. Pricing sources are the one shelf that expires — which is why every pricing citation on this site carries a verification date.